Disubstituted phthalazine hedgehog pathway antagonists
First Claim
1. A method of treating cancer selected from the group consisting of brain cancer, basal cell carcinoma, esophagus cancer, gastric cancer, pancreatic cancer, biliary tract cancer, prostate cancer, breast cancer, small-cell lung cancer, non-small cell lung cancer, B-cell lymphoma, multiple myeloma, ovarian cancer, colorectal cancer, liver cancer, kidney cancer, melanoma, head and neck cancer, soft tissue sarcomas, bone sarcomas, and leukemia in a mammal comprising administering to the mammal an effective amount of a compound which is 4-fluoro-N-methyl-N-(1-(4-(1-methyl-1H-pyrazol-5-yl)phthalazin-1-yl)piperidin-4-yl)-2-(trifluoromethyl)benzamide, or a pharmaceutically acceptable salt thereof.
0 Assignments
0 Petitions
Accused Products
Abstract
The present invention provides novel 1,4-disubstituted phthalazine hedgehog pathway antagonists useful in the treatment of cancer.
-
Citations
6 Claims
- 1. A method of treating cancer selected from the group consisting of brain cancer, basal cell carcinoma, esophagus cancer, gastric cancer, pancreatic cancer, biliary tract cancer, prostate cancer, breast cancer, small-cell lung cancer, non-small cell lung cancer, B-cell lymphoma, multiple myeloma, ovarian cancer, colorectal cancer, liver cancer, kidney cancer, melanoma, head and neck cancer, soft tissue sarcomas, bone sarcomas, and leukemia in a mammal comprising administering to the mammal an effective amount of a compound which is 4-fluoro-N-methyl-N-(1-(4-(1-methyl-1H-pyrazol-5-yl)phthalazin-1-yl)piperidin-4-yl)-2-(trifluoromethyl)benzamide, or a pharmaceutically acceptable salt thereof.
Specification
-
- Resources
-
Current AssigneeEli Lilly and Company
-
Original AssigneeEli Lilly and Company
-
InventorsHipskind, Philip Arthur, Patel, Bharvin Kumar, Wilson (nee Takakuwa), Takako
-
Primary Examiner(s)Murray, Jeffrey H
-
Assistant Examiner(s)MASHA, OLUWAFEMI L
-
Application NumberUS13/590,481Publication NumberTime in Patent Office959 DaysField of Search514/248US Class Current514/403CPC Class CodesA61P 25/02 for peripheral neuropathiesA61P 35/00 Antineoplastic agentsA61P 35/02 specific for leukemiaA61P 35/04 specific for metastasisA61P 43/00 Drugs for specific purposes...C07D 401/14 containing three or more he...
